Wednesday, November 29, 2023
1:30 PM-2:30 PM ET
Professor of Medicine
Division of General Internal Medicine
Emory University School of Medicine
This activity is jointly provided by Purdue University College of Pharmacy and Integritas Communications.
This activity is supported by independent educational grants from Gilead Sciences, Inc., and AbbVie Inc.
This educational initiative is intended for primary care clinicians, community treaters, hepatologists, gastroenterologists, infectious disease specialists and other healthcare providers currently treating HCV.
Upon completion of this program, participants will be better able to:
- Discuss national and local epidemiologic data on HCV-positive PWID within the context of the opioid crisis
- Describe the feasibility, effectiveness, and population benefits of treating HCV-infected PWID
- Prescribe DAA-drug regimens for the treatment of HCV-infected PWID
- Apply harm-reduction principles and practices across the HCV-care continuum
- Evaluate peer-navigation support needs and capacities within the practice setting
This exciting grassroots initiative will tap into the strengths and resources of communities in inner-city and metropolitan areas to provide effective therapy for HCV-positive PWID. Expansion of DAA treatment to individuals with recent or ongoing injection drug use can lead to substantial reductions in HCV prevalence and transmission, benefiting both the individual and the community. These benefits are especially effective when combined with harm-reduction interventions.1 Strong local HCV-care networks with structured collaboration further help build bridges to HCV-infected PWID and allow these high-risk individuals access to the care they need and deserve.2
The initiative’s live educational meetings for small, community-based groups of health care professionals will offer medical and addiction-services specialists cutting-edge strategies to collaboratively reach and treat HCV-positive PWID. Presenting the critical balance between clinical data and real-world experience and insights,3 these educational events will give participants the opportunity to interact directly with HCV and harm-reduction experts as well as resources to use and share in the practice setting.
- Grebely J, Dore GL. Treatment of HCV in persons who inject drugs: Treatment as prevention. Clin Liver Dis. 2017;9(4):77-80.
- Gonzalez SA, et al. Medical and behavioral approaches to engage people who inject drugs into care for hepatitis C virus infection. Addict Disord Their Treat. 2017;16(2 suppl 1):S1-S23.
- Wilson DP, et al. The cost-effectiveness of harm reduction. Int J Drug Policy. 2015:26(suppl 1):S5-S11.
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and Integritas Communications. Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Purdue University College of Pharmacy designates this Live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacist Accreditation Statement
Purdue University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge-based, continuing education activity of Purdue University, an equal access/equal opportunity institution. Universal Activity Number (UAN): 0018-9999-22-038-L01-P, 1.0 contact hour (0.1 CEU).
Nurses Accreditation Statement
Purdue University Continuing Nursing Education is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This program has been approved for 1.0 contact hour.
Disclosure of Conflicts of Interest
The Purdue University College of Pharmacy requires instructors, planners, managers, and other individuals who are positioned to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to The Purdue University College of Pharmacy policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.
Americans with Disabilities Act
Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Mara Simpson prior to the live event at firstname.lastname@example.org.
There is no fee for this educational activity.
Purdue Contact Information
For information about the accreditation of this program, please contact Dawn Sinclair at The Purdue University College of Pharmacy at email@example.com or 765-494-5457.